Vertex Pharmaceuticals Incorporated (VRTX) reported quarterly earnings results on Wednesday, Apr-27-2016. The company reported $0.09 earnings per share for the quarter, missing the analyst consensus estimate by $-0.19. Analysts had a consensus of $0.28. The company posted revenue of $398.10 million in the period, compared to analysts expectations of $438.21 million. The company’s revenue was up 187.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.62 EPS.
Many Wall Street Analysts have commented on Vertex Pharmaceuticals Incorporated. Shares were Reiterated by Stifel on Apr 1, 2016 to “Buy” and Lowered the Price Target to $ 108 from a previous price target of $140 .Shares were Reiterated by RBC Capital Mkts on Mar 18, 2016 to “Outperform” and Lowered the Price Target to $ 135 from a previous price target of $145 .Shares were Reiterated by Argus on Feb 4, 2016 to “Buy” and Lowered the Price Target to $ 140 from a previous price target of $154 .
Vertex Pharmaceuticals Incorporated closed down -0.01 points or -0.01% at $86.8 with 12,78,986 shares getting traded on Friday. Post opening the session at $86.36, the shares hit an intraday low of $84.08 and an intraday high of $87.38 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Apr 22, 2016, Joshua S Boger (director) sold 5,130 shares at $84.38 per share price. According to the SEC, on Feb 4, 2016, Ian F Smith (EVP & CFO) sold 12,084 shares at $91.32 per share price. On Feb 4, 2016, Paul M Silva (SVP & Corp Controller) sold 5,062 shares at $91.63 per share price, according to the Form-4 filing with the securities and exchange commission.
Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering developing manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertexs business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs including programs in the areas of oncology and neurology. The Companys product candidates include KALYDECO (ivacaftor) Lumacaftor in combination with Ivacaftor VX-661 in combination with Ivacaftor VX-803 VX-970 and VX-222. The Companys product KALYDECO is available in the market.